|
Brugada syndrome. |
|
|
Auerbach H, Blank R, Jank K, Gronefeld G, Klingenheben T, Marschall C, von Mengden HJ. |
|
|
Brugada syndrome, a rare cause of syncope. |
|
|
Brugada syndrome following tricyclic antidepressant overdose. |
|
|
Prevalence and Clinical Course of the Juveniles with Brugada-Type ECG in Japanese
Population. |
|
|
Schulze-Bahr E, Eckardt L, Breithardt G, Seidl K, Wichter T, Wolpert C, Borggrefe M, Haverkamp W. |
|
|
Erratum: Sodium channel gene (SCN5A) mutations in 44 index patients with brugada
syndrome: Different incidences in familial and sporadic disease. |
|
|
Suppression of electrical storm by oral quinidine in a patient with Brugada
syndrome. |
|
|
Brugada syndrome |
|
|
Brugada syndrome. |
|
|
Shan QJ, Yang B, Chen ML, Zou JG, Xu DJ, Chen C, Li KL, Zhu PJ, Wang XB, Cao KJ. |
|
|
The electrophysiological study and implantable cardioverter defibrillator
therapy for the patients with Brugada syndrome |
|
|
Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder,
repolarization disorder, or more? |
|
|
A mutation in the human cardiac sodium channel (E161K) contributes to sick
sinus syndrome, conduction disease and Brugada syndrome in two families. |
|
|
Brugada syndrome: report of the second consensus conference. |
|
|
Specific therapy based on the genotype and cellular mechanism in inherited
cardiac arrhythmias. Long QT syndrome and Brugada syndrome. |
|
|
Brugada syndrome and fever: Genetic and molecular characterization of patients
carrying SCN5A mutations. PMID: 15890323 [PubMed - as supplied by publisher] |
|
|
Brugada syndrome. |
|
|
Brugada syndrome--an update. |
|
|
A novel missense mutation in the SCN5A gene associated with Brugada syndrome
bidirectionally affecting blocking actions of antiarrhythmic drugs. |
|
|
Skinner JR, Chung SK, Montgomery D, McCulley CH, Crawford J, French J, Rees MI. |
|
|
Near-miss SIDS due to Brugada syndrome. |
|
|
Unconventional intronic splice site mutation in SCN5A associates with cardiac
sodium channelopathy. |
|
Sugao M, Fujiki A, Sakabe M, Nishida K, Tsuneda T, Iwamoto J, Mizumaki K, Inoue H. |
|
|
New quantitative methods for evaluation of dynamic changes in QT interval
using 24-hour Holter ECG recordings: QT interval in idiopathic ventricular
fibrillation and long QT syndrome. |
|
|
Shang YP, Xie XD, Wang XX, Chen JZ, Zhu JH, Tao QM, Zheng LR. |
|
|
A novel splice mutation of HERG in a Chinese family with long QT syndrome. |
|
|
Specific therapy based on the genotype and cellular mechanism in inherited
cardiac arrhythmias. Long QT syndrome and Brugada syndrome. |
|
|
Pathogenesis of unexplained drowning: new insights from a molecular autopsy. |
|
|
Wilson AJ, Quinn KV, Graves FM, Bitner-Glindzicz M, Tinker A. |
|
|
Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long
QT syndromes (LQT1). |
|
|
Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. |
|
|
Is there a relation between SIDS and long QT syndrome? |
|
|
Unconventional intronic splice site mutation in SCN5A associates with cardiac
sodium channelopathy. |
|
|
Molecular predictors of drug-induced prolongation of the QT interval. |
|
|
Kanters JK, Fanoe S, Larsen LA, Bloch Thomsen PE, Toft E, Christiansen M. |
|
|
T wave morphology analysis distinguishes between KvLQT1 and HERG mutations
in long QT syndrome. |
|
|
Dominant-negative I(Ks) suppression by KCNQ1-DeltaF339 potassium channels
linked to Romano-Ward syndrome. |
|
|
Tan BH, Valdivia CR, Rok BA, Ye B, Ruwaldt KM, Tester DJ, Ackerman MJ, Makielski JC. |
|
|
Common human SCN5A polymorphisms have altered electrophysiology when expressed
in Q1077 splice variants. |
|
|
Genetic Polymorphisms and Haplotypes of the Human Cardiac Sodium Channel alpha
Subunit Gene (SCN5A) in Japanese and their Association with Arrhythmia. |
|
|
Automated electrophysiology in the preclinical evaluation of drugs for potential
QT prolongation. |
|
|
Paulussen AD, Raes A, Jongbloed RJ, Gilissen RA, Wilde AA, Snyders DJ, Smeets HJ, Aerssens J. |
|
|
HERG mutation predicts short QT based on channel kinetics but causes long
QT by heterotetrameric trafficking deficiency. |
|
|
Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. |
|
|
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of
dofetilide clinical QT prolongation from human ether-a-go-go-related gene
current inhibition data. |
|
|
Dorn A, Hermann F, Ebneth A, Bothmann H, Trube G, Christensen K, Apfel C. |
|
|
Evaluation of a high-throughput fluorescence assay method for HERG potassium
channel inhibition. |
|
|
Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. |
|
|
HERG-Lite(R): A novel comprehensive high-throughput screen for drug-induced
hERG risk. |
|
|
Estimation of potency of HERG channel blockers: Impact of voltage protocol
and temperature. |
|
|
Additive effects of ziprasidone and d,l-sotalol on the action potential in
rabbit Purkinje fibres and on the hERG potassium current. |
|
|
A discriminant model constructed by the support vector machine method for
HERG potassium channel inhibitors. |
|
|
Miranda P, Giraldez T, de la Pena P, Manso DG, Alonso-Ron C, Gomez-Varela D, Dominguez P, Barros F. |
|
|
Specificity of TRH receptor coupling to G-proteins for regulation of ERG K+
channels in GH3 rat anterior pituitary cells. |
|
|
Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration
of the novel anti-arrhythmic compound AZD7009. |
|
|
Differential effects of human ether-a-go-go-related gene (HERG) blocking agents
on QT duration variability in conscious dogs. |
|
|
HERG K+ channel expression-related chemosensitivity in cancer cells and its
modulation by erythromycin. |
|
|
Human Ether-a-go-go Related Gene (HERG): A Chemist's Perspective. |
|
|
Intracellular K+ is required for the inactivation-induced high affinity binding
of cisapride to HERG channels. |
|
|
Molecular mapping of a binding site for Cd2+- induced modification of hERG
channel activation. |
|
|
Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, Cordes JS. |
|
|
Novel Potent hERG Potassium Channel Enhancers And Their In Vitro Antiarrhythmic
Activity. |
|
|
Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, Cruciani G, Vaz RJ. |
|
|
Predictive models for hERG potassium channel blockers. |
|
|
Matasi JJ, Caldwell JP, Zhang H, Fawzi A, Higgins GA, Cohen-Williams ME, Varty GB, Tulshian DB. |
|
|
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine
A(2A) antagonists: The successful reduction of hERG activity. Part 2. |
|
|
Local Anesthetic Interaction with Human Ether-a-go-go-related Gene (HERG)
Channels: Role of Aromatic Amino Acids Y652 and F656. |
|
|
{omega}-3 and {omega}-6 Polyunsaturated Fatty Acids block HERG Channels. |
|
Lerecouvrex M, Ait Said M, Paziaud O, Perrier E, Carlioz R, Lavergne T, Guize L, Le Heuzey JY. |
|
|
Automobile driving and implantable defibrillators |
|
|
Sudden infant death syndrome: How significant are the cardiac channelopathies? |
|
|
Cardiovascular pre-participation screening of young competitive athletes for
prevention of sudden death: proposal for a common European protocol; reply. |
|
|
Nonclinical proarrhythmia models: Predicting Torsades de Pointes. |
|
|
Supraventricular Tachycardia with a Baseline ECG Pattern of Brugada Syndrome. |
 |
PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.